The BU database was compiled through a systematic search of peer-reviewed literature and inclusion of routine surveillance data collected by control programmes responsible for BU in endemic countries. The database includes occurrence records of BU disease in humans and animals, and of evidence of Mycobacterium ulcerans detection in environmental and animal samples, each linked to a point or polygon location.
The diagnostic specificity score ranged from 0.5 to 1. The maximum score for was given for records where confirmation by PCR indicating M. ulcerans, or histopathological analysis indicating BU disease was reported. Although the WHO case definition for a confirmed case requires at least two positive confirmatory tests (3), we decided not to down-weight cases with only one confirmatory test result because multiple testing is uncommon due to the higher resource requirements, and comparative analysis of different confirmatory testing methods has shown the common tests to have a high specificity when used individually (4) . However, records where cases were confirmed by Ziehl Neelsen (ZN) staining and/or culture alone were down-weighted by 5%, reflecting the possibility of detection of other mycobacteria by these methods (5, 6) . The score was down-weighted by 50% if cases were clinically diagnosed only. If the publication reported that proportion of cases were laboratory-confirmed, but did not present the confirmation status of cases at unique locations, the record was considered unconfirmed at local-level, and confirmed at the national-level.
The contemporariness and diagnosis scores were summed to provide local-and national-level evidence quality scores for each occurrence record. Local evidence quality scores were converted to percentages, which were used as weights to adjust the total number of cases reported at each location.
For countries from which strains of M. ulcerans were reported to have been isolated, but with no evidence of reported cases meeting the inclusion criteria, the evidence score was adjusted post-hoc.
S.1.4. Data quality score for environmental detection of M. ulcerans DNA and BU disease in animals
Various PCR targeting techniques with varying sensitivities and specificities are used for M. ulcerans
detection. The conventional PCR target for confirmation of human cases is the IS (insertion sequence)
2404, present at high copy number in the M. ulcerans genome (7) , and providing high sensitivity and specificity (8, 9) . This target can also be used to indicate probable presence of M. ulcerans in the environment, but its sensitivity and specificity are reduced by the existence of PCR inhibitors and of other mycobacteria carrying the same gene within environmental samples. Other PCR targets available include the IS2606, and sequences encoding the enoyl reductase (ER) and ketoreductase-B (KR-B) domains, which form part of the mycolactane polyketide synthase genes [ref] . These genes are also present in other mycolactane-producing mycobacteria (MPM), but at different copy numbers (7) . Recently developed multiplex qPCR assays targeting IS2404, IS2606 and the KR-B domain and quantifying their respective copy numbers allow discrimination of M. ulcerans from other MPM (7) .
Variable nucleotide tandem repeat (VNTR) and mycobacterial interspersed repetitive unit (MIRU) typing can also be used to distinguish M. ulcerans from other MPM (10) based on the copy numbers of short repeating DNA sequences found at multiple loci within the genome (11) .
According to the varying discriminatory power of these typing methods, we assigned the maximum typing score to samples confirmed as M. ulcerans by multiplex qPCR or VNTR analysis, a lower score for samples typed only by conventional PCR analysis targeting IS2404, IS2606, ER or KR-B, alone or in combination. Samples confirmed as MPM other than M. ulcerans (by qPCR or VNTR typing) were down-weighted by 75% relative to those confirmed as M. ulcerans, on the assumption that these organisms may share a similar niche to M. ulcerans, and indeed have been considered by some authors to be part of the same species (12) .
Each environmental/animal occurrence record was given a data quality score from 0-3 based on:
Typing specificity (0-2):
• confirmed as MPM other than M. ulcerans = 0. Within each administrative unit, the scores were summed to give a score from 0-4, and converted to a percentage for mapping.
S.2. Evidence consensus framework
An evidence consensus framework was used to assign scores reflecting the strength of evidence for BU presence and absence at national level. A separate framework was used to assess the strength of evidence for BU presence at the highest sub-national administrative level (adm1) within countries with evidence of BU presence.
For countries with reported evidence of BU cases, four main data sources were used for the evidence consensus: i) BU data reported nationally to WHO from [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] , ii) reports of BU disease to GIDEON, iii) reports of cases in peer-reviewed literature, and iv) cases recorded by surveillance programmes or public health laboratories in BU-endemic countries. These were converted to three constituent scores: health organisation status, occurrence data quality, and case number.
The occurrence data quality score was based on the highest national data quality score assigned to each occurrence record. Countries with no occurrence data were assigned a score of 0, and those with occurrence data were assigned a score of up to 3 (if cases were recorded since 2003 and laboratoryconfirmed).
The case number score was based on the total number of cases in all occurrence records, each adjusted by its local-level evidence quality score. Countries reporting more than 20 cases (postadjustment) were given a score of 1, those reporting 11-20 were down-weighted by 25%, those reporting 4-10 were down-weighted by 50%, and those reporting fewer than 4 cases were downweighted by 75%.
Consensus presence was assigned if cases had been reported to WHO between 2002 and 2018; BU had been reported through GIDEON; at least one laboratory confirmed case had been recorded in peer-reviewed literature or by the national programme (for countries which had contributed surveillance data); and if a minimum number had been reported from all sources-the minimum threshold ranged from 20, if all cases were laboratory confirmed and reported since 2003, and was scaled up depending on the proportions unconfirmed and reported prior to 2003.
If there was no evidence of BU from any of the data sources included, the evidence consensus score was designed to quantify the strength of evidence for BU absence, reflecting the possibility of cases being under-reported due to weak surveillance or reporting capacity, or being masked due to misdiagnosis as known endemic diseases that share diagnostic presentations with BU (potential confounding diseases).
The potential confounding diseases with evidence available on their global distribution were cutaneous leishmaniasis (CL), leprosy, lymphatic filariasis (LF), onchocerciasis and tropical ulcer (TU), all of which have at least one possible presentation in common with BU (including nodules, plaques, oedema and ulcers) (13) . The country-level endemicity of these diseases was based on evidence consensus mapping for CL (14, 15) ; literature review for yaws (16) , GIDEON data for TU (17) ; the rapid epidemiological mapping of onchocerciasis (REMO) (18) ; and on reporting of leprosy to WHO from 2012-2016 (data provided on request by the WHO Leprosy team).
Estimates of the proportional frequencies of the most common presentations of BU and the potential confounding diseases were obtained from literature review (18) (19) (20) (21) (22) and expert opinion, using crosssectional survey data preferentially to health facility data, as the latter would tend to overestimate the proportion of cases with more severe presentations. Prevalence of onchocerciasis in the REMO study was based only on nodule prevalence, so the frequency of nodules among onchocerciasis cases was set at 100%.
For each disease, the proportional frequencies of the presentations shared with BU were multiplied by the proportional frequency of the corresponding presentation in BU cases, and the products summed to generate a symptom overlap score, reflecting the likelihood of misdiagnosis of BU as that disease (Supplementary Figure S1 , Table S.1). For each country, misdiagnosis likelihood scores for all endemic confounding diseases were summed and standardised to a percentage, representing a composite misdiagnosis likelihood score.
Health expenditure values (HE; average expenditure from 2011-2015, from all financing sources, expressed in constant (2010) USD per capita) reported by the WHO (23) were used as a proxy for diagnostic capacity and for surveillance and reporting capacity, following the approach of previous authors (15, 24, 25) and supported by evidence that a higher level of health expenditure is associated with better health system performance (26) . Countries with HE <$100 were categorised as low, those with $100≤HE<$500 were categorised as medium, and those with HE≥$500 were categorised as high.
Two separate health system scores were assigned based on HE category. The first was used to adjust composite misdiagnosis likelihood scores, reflecting lower likelihood of misdiagnosis of BU in countries with higher health expenditure, assuming a higher diagnostic capacity. The final composite misdiagnosis likelihood score was intended to indicate the likelihood of BU being misdiagnosed as any of the confounding diseases in each country. HE was also used to assign a score representing surveillance and reporting capacity. Countries with low HE were considered most likely to be underdetecting or not reporting BU so were assigned a score of 1, while those with high HE were assigned a score of 0.
Consensus absence was assigned to countries with no evidence of BU cases reported through WHO or GIDEON, or in peer-reviewed literature, no evidence of endemicity of the potential confounding diseases considered, and high health expenditure. Countries endemic for all the confounding diseases and with low HE scored 0, reflecting indeterminate BU endemicity status.
S.3. Quality assessment framework for BU prevalence surveys
This framework is adapted from Deribe et al. (27) , and grades surveys on an 8 point scale using 4 quality assessment elements:
A. Definition of sampling frame 0. No information beyond overall population type (e.g. "schools" or "households") Literature review scores D, C, and DQ show the scores assigned to the highest-scoring reference, based on diagnostic specificity (D) and contemporariness (C), combined to give a data quality (DQ) score. The total cases (TC) is the sum of the total number of cases reported in all references included in the review, each weighted according to the data quality score for the reference. Health expenditure level (HE L) was used to assign health system (HS) scores 1 and 2. Misdiagnosis scores were calculated for a range of conditions that present on the skin, based on the proportion of symptoms shared with BU. The composite misdiagnosis likelihood score (CMP) is the sum of the misdiagnosis scores for all endemic diseases in each country, weighted by HS1 which represents the quality of diagnosis. 
